Eaddy, Michael <br/><br/>
Establishing the clinical and economic benefits of adherence to 5-alpha reductase inhibitors in benign prostatic hyperplasia: an assessment of Medicare and Medicaid patients.  [electronic resource] 

 -  Expert opinion on pharmacotherapy  Dec 2012 
 - 2593-600 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1744-7666 
<br/><br/><label>Standard No.: </label>10.1517/14656566.2012.744821  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>5-alpha Reductase Inhibitors--administration & dosage<br/>Aged<br/>Aged, 80 and over<br/>Cohort Studies<br/>Cost Savings<br/>Databases, Factual<br/>Follow-Up Studies<br/>Health Care Costs<br/>Humans<br/>Male<br/>Medicaid<br/>Medicare<br/>Medication Adherence<br/>Middle Aged<br/>Proportional Hazards Models<br/>Prostate--drug effects<br/>Prostatic Hyperplasia--drug therapy<br/>Retrospective Studies<br/>United States<br/>Urinary Retention--economics